Hypertension as an autoimmune and inflammatory disease.

Permalink
https://escholarship.org/uc/item/3t88w7k0

Journal
Hypertension research : official journal of the Japanese Society of Hypertension, 39(8)

ISSN
0916-9636

Authors
Solak, Yalcin
Afsar, Baris
Vaziri, Nosratola D
et al.

Publication Date
2016-08-01

DOI
10.1038/hr.2016.35

Peer reviewed
Hypertension as an autoimmune and inflammatory disease

Yalcin Solak¹, Baris Afsar², Nosratola D Vaziri³, Gamze Aslan⁴, Can Ege Yalcin⁵, Adrian Covic⁶ and Mehmet Kanbay⁷

Hypertension that is considered idiopathic is called essential hypertension and accordingly has no clear culprit for its cause. However, basic research and clinical studies in recent years have expanded our understanding of the mechanisms underlying the development of essential hypertension. Despite achieving considerable progress, the intricate interactions between oxidative stress, the immune system and the development of hypertension remain to be fully elucidated. In this review, we summarize recent developments in the pathophysiology of hypertension with a focus on the oxidant stress–autoimmunity–inflammation interaction.

Keywords: autoimmune disease; inflammation

INTRODUCTION
Hypertension is the most common chronic disease and the major cause of heart failure, stroke, chronic kidney disease and mortality in the Western world. Similar to other disease states, idiopathic hypertension is called ‘essential’ or ‘primary’ when its exact cause and pathophysiology are unknown. Known, direct causes of hypertension are identified in only 5–10% of all cases and are designated as ‘secondary’ owing to a precise underlying pathophysiological mechanism. Recent advances have considerably expanded our understanding of the underlying mechanisms of primary hypertension. Several lines of experimental and clinical evidence point to the important role of oxidative stress and inflammation in the development of hypertension. At the same time, it is important to determine whether autoimmunity and inflammation/oxidative stress lead to hypertension or vice versa. This review provides an overview of the current evidence relating increased oxidative stress, inflammation and autoimmune alterations to the development and progression of hypertension, with a special focus on causation (Figure 1).

HUMAN STUDIES IDENTIFYING THE ROLE OF INFLAMMATION IN HYPERTENSION
Several cross-sectional studies have reported an increased level of inflammation in patients with hypertension. In a cross-sectional survey of 8347 apparently healthy Korean individuals, Sung et al.¹ found that the prevalence of hypertension was 1.267-, 1.253- and 1.451 times higher in subjects from the second, third and fourth quartiles of the C-reactive protein (CRP) distribution, respectively, compared with subjects in the first quartile, even after the adjustment for many confounders (CRP level ranges for the first and fourth quartiles were 0.1–0.3 and 1.2–11 mg l⁻¹, respectively). Similarly, Bautista et al.² showed that patients in the third and fourth quartiles of the interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) distribution were more likely to have hypertension compared with patients in the first quartile. These and other studies³ recruited apparently healthy individuals and assessed inflammatory markers along with a number of laboratory, clinical and demographic features described as independent predictors of elevated blood pressure. Despite the demonstration of an independent association between increased inflammatory markers, such as CRP, IL-6 and TNF-α, and hypertension, these associative studies did not address the question of which condition precedes the other. Several observational studies answered this question. These studies recruited normotensive subjects, followed them and documented the development of de novo hypertension, and the baseline inflammatory status was evaluated as a predictive factor for the development of hypertension. Sesso et al.⁴ investigated a prospective cohort of

¹Department of Internal Medicine, Division of Nephrology, Sakarya University Training and Research Hospital, Sakarya, Turkey; ²Department of Medicine, Division of Nephrology, Konya Numune State Hospital, Konya, Turkey; ³Department of Medicine, Division of Nephrology and Hypertension, Schools of Medicine and Biological Science, University of California Irvine, California, CA, USA; ⁴Department of Cardiology, Koc University School of Medicine, Istanbul, Turkey; ⁵Department of Medicine, Koc University School of Medicine, Istanbul, Turkey; ⁶Nephrology Clinic, Dialysis and Renal Transplant Center, ‘CI PARHON’ University Hospital, and ‘Gregore T Popa’ University of Medicine, Iasi, Romania and ⁷Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey

Correspondence: Dr M Kanbay, Department of Medicine, Division of Nephrology, Koc University School of Medicine, Sariyer, Istanbul 03410, Turkey.
E-mail: mkanbay@ku.edu.tr and drkanbay@yahoo.com

Received 14 December 2015; revised 24 February 2016; accepted 29 February 2016; published online 7 April 2016
Hypertension Research

568

**Figure 1** Interconnection of hypertension, inflammation, oxidative stress and the immune system. CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α. A full color version of this figure is available at the Hypertension Research journal online.

20,525 female US health professionals aged >45 years who were normotensive at baseline evaluation. These women were followed for a median of 7.8 years and incident hypertension cases were recorded. CRP at baseline was significantly associated with an increased risk of developing hypertension in all subgroups of individuals, including those with very low levels of baseline blood pressures, as well as those with no traditional coronary risk factors. Of 5365 women who developed hypertension, 511 had baseline serum CRP value <0.43 mg l⁻¹, whereas 1962 individuals had serum CRP values of >3.50 mg l⁻¹; the remaining incident hypertensive patients had CRP values in between. In adjusted models, a 1 s.d. increase of CRP led to a 1.14 adjusted relative risk for incident hypertension. The same group conducted a nested case-control study of 400 women developing hypertension and an equal number of age-matched normotensive control subjects for 10 years of follow-up as part of the Women’s Health Study. The authors found that after multivariate adjustment, IL-6 was weakly associated and CRP was strongly associated with the risk of hypertension. Several other studies confirmed this temporal relationship in patients with prehypertension or in elderly normotensive individuals.6,7

In summary, several studies support an independent association between several markers of inflammation and hypertension. Most importantly, increased inflammation clearly preceded clinical blood pressure elevation. Altogether, these studies support the hypothesis that inflammation may be causally related to the development of elevated blood pressure.

**EXPERIMENTAL DATA AND POSSIBLE PATHWAYS FOR INFLAMMATION-INDUCED HYPERTENSION**
Clinical studies suggest an independent link between systemic inflammation and an increased risk of hypertension. However, another question is how does this increased systemic inflammation lead to the development of hypertension? And, could this systemic inflammation be related to inflammation in tissues vital for the development of hypertension, namely the vascular wall and/or the kidney?

Numerous well-designed experimental studies conducted on spontaneously hypertensive rats (SHRs) revealed the significance of renal interstitial inflammation and increased oxidative stress in the development of hypertension. Previously, inflammatory infiltration and immune dysfunction observed in SHR were considered part of the defense mechanism and therefore a secondary consequence to the development of hypertension.8 However, subsequent studies suggested that immune cell infiltration in the kidney may be the cause, not the result, of hypertension in this model. Indeed, in nearly all models of salt-sensitive hypertension, the tubulointerstitium of rat kidneys are infiltrated with lymphocytes and macrophages, and a correlation between the intensity of the inflammatory cell infiltration and the severity of the blood pressure elevation was apparent. In experimental models of hypertension, monocyte/macrophage infiltration of the perivascular fat renal tissue, as well as vascular adventitia, was observed. Furthermore, several experimental studies, in which renal tubulointerstitial inflammation was reduced using various methods, either prevented the development of hypertension altogether or ameliorated hypertension in genetic models of hypertension. Putative mechanisms by which increased renal interstitial inflammation leads to the development of hypertension include increased oxidative stress, loss of peritubular capillaries and resultant medullary hypoxia, and an impaired pressure natriuresis mechanism. Details of the mechanisms by which renal interstitial inflammation may cause hypertension have been recently reviewed elsewhere.

Evidence showing the effects of renal interstitial infiltration also comes from experimental studies that investigated the impact of anti-inflammatory cytokines, such as IL-10, on blood pressure. Tinsley et al. showed that the administration of intraperitoneal IL-10 normalized blood pressure and improved endothelial dysfunction in pregnant deoxycorticosterone acetate/saline-treated rats. More recently, Dhande et al. administered an AT2 receptor agonist to a monocyte cell line cell culture. The AT2 receptor agonist increased IL-10 production but decreased lipopolysaccharide-induced TNF-α and IL-6 production in a dose-dependent manner. As stated earlier, macrophage infiltration is almost universal in hypertension models.
Clinical studies confirmed that in patients with essential hypertension, blood pressure levels are positively correlated with markers of oxidative stress. In addition, population-based observational studies demonstrated an inverse correlation between plasma antioxidant levels and blood pressure levels.

An increased local ROS concentration in the kidney may have a pivotal role in the generation of hypertension. ROS-induced vascular remodeling impairs autoregulation and may lead to distal tubulointerstitial ischemia. In genetically hypertensive rats, the number of intrarenal supr oxide-producing cells is positively correlated with systolic blood pressure levels. Recently, resveratrol was shown to mitigate oxidative stress and normalize angiotensin signaling in the kidney and reduce blood pressure via activation of phase II antioxidant enzymes.

Aortic stiffening is associated with the development of hypertension. A common denominator of various conditions associated with aortic stiffening is increased vascular oxidative stress. Increased oxidative stress in the vascular wall is closely related to inflammatory infiltration. Several researchers postulated the role of modification of self-proteins, such as isoketals, also known as isoleucyl-arginines. The modified self-proteins then behave as autoantigens and elicit an inflammatory reaction. Wu et al. used a mouse model exhibiting excessive vascular production of ROS and observed that the animals developed vascular collagen deposition, aortic stiffening, renal dysfunction and hypertension with aging. Thus, increased oxidative stress may be a major culprit in the development of inflammatory infiltration, fibrosis and ensuing elevated blood pressures.

In summary, increased oxidative stress in renal and arteriolar vascular tissues may lead to increased blood pressure and could be an effector pathway for a number of pathophysiological disorders. The Harrison group proposed that oxidative stress behaves as the effector mechanism and final common pathway for a number of pathophysiological conditions, including immune, endocrine, neural, vascular and genetic disorders (mosaic theory of hypertension). There is significant evidence showing increased inflammation as well as oxidative stress in the renal interstitium and vascular wall, but the question remains as to why only some individuals who suffer from increased oxidative stress and inflammation develop hypertension whereas others do not.

The clearcut answer to this essential question has yet to be determined, but polymorphisms in antioxidant system enzymes, such as glutathione S-transferase and NADPH oxidase, may account for the interindividual differences in the levels of pro-oxidant molecules and antioxidative capacity. The autoimmune response against some undefined antigens may be another factor responsible for the development of hypertension. Clinical studies related to hypertension and inflammation are summarized in Table 1.

**ADAPTIVE IMMUNE SYSTEM IN THE PATHOGENESIS OF HYPERTENSION**

Studies identifying the role of the innate/adaptive immune system in the development of hypertension were performed in the 1980s, but reported conflicting results, which made it difficult to reconcile differences and decreased interest in this field. We now propose that different subtypes of immune cells, with various and considerably different functions, may have led to such conflicting results. A better understanding of the various cell subtypes and corresponding functions has allowed scientists to conduct new studies with promising results, which implicate several aspects of immune dysregulation in the pathophysiology of hypertension.

As discussed earlier in this review, an inflammatory infiltrate mainly composed of monocyte/macrophages (innate) is related to increased
### Table 1: Clinical studies related to hypertension and inflammation

<table>
<thead>
<tr>
<th>Trial, (year)</th>
<th>Study type</th>
<th>Patient number</th>
<th>Age (years)</th>
<th>Aim of the study</th>
<th>Follow-up period (years)</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sesso et al.6</td>
<td>Prospective cohort</td>
<td>20 525</td>
<td>N/A</td>
<td>To assess if CRP is associated with incident hypertension</td>
<td>7.8 years</td>
<td>There is a statistically significant association between CRP and risk of developing hypertension</td>
</tr>
<tr>
<td>Bautista et al.69</td>
<td>Case-control</td>
<td>904</td>
<td>43.1 ± 2.9</td>
<td>To examine whether CRP is associated with high BP</td>
<td>N/A</td>
<td>Prevalence of hypertension increases progressively as serum CRP levels get higher</td>
</tr>
<tr>
<td>Kashyap et al.69</td>
<td>Cross-sectional</td>
<td>100</td>
<td>N/A</td>
<td>To investigate and compare the antioxidant status in essential hypertension patients to normotensive subjects, by using variables such as FRAP, free radicals and other antioxidants</td>
<td>N/A</td>
<td>Patients with essential hypertension had significantly higher levels of total cholesterol, LDL, VLDL, homocysteine in addition to lower levels of HDL, reduced and total glutathione, total antioxidant power</td>
</tr>
<tr>
<td>Lakoski et al.70</td>
<td>Prospective cohort</td>
<td>3919</td>
<td>32</td>
<td>To investigate the role of CRP as an independent risk factor for developing hypertension in young adults</td>
<td>7 years</td>
<td>CRP is associated with hypertension in young adults, but in contrast to the finding in older populations, the association is no longer present after adjusting for BMI</td>
</tr>
<tr>
<td>Sesso et al.5</td>
<td>Nested case-control study</td>
<td>800</td>
<td>54.5 ± 6.7</td>
<td>To demonstrate the relationship between serum IL-6 and CRP levels with the risk of developing hypertension</td>
<td>10 years</td>
<td>IL-6 was weakly associated and CRP strongly associated with hypertension risk</td>
</tr>
<tr>
<td>Rodrigo et al.71</td>
<td>Cross-sectional</td>
<td>89</td>
<td>43.4 ± 1.1</td>
<td>To assess if increased lipid peroxidation leading to cell membrane changes is associated with an elevated BP through an effect on Na+/K+-ATPase</td>
<td>N/A</td>
<td>Modulation of Na+/K+-ATPase activity may be associated with changes in the fatty acid composition induced by oxidative stress and provide evidence of a role for this enzyme in the pathophysiology of essential hypertension.</td>
</tr>
<tr>
<td>Rodrigo et al.72</td>
<td>Cross-sectional</td>
<td>66</td>
<td>44.4 ± 1.3</td>
<td>To demonstrate any possible associations between BP and oxidative stress</td>
<td>N/A</td>
<td>There is a strong association between BP and some oxidative stress-related parameters</td>
</tr>
<tr>
<td>Rodrigo et al.73</td>
<td>Randomized placebo-controlled study</td>
<td>220</td>
<td>44.1 ± 0.9</td>
<td>To test whether antioxidant properties of vitamin C and E are able to cause a decrease in BP</td>
<td>8 weeks of treatment period</td>
<td>Vitamin C and E intake is associated with a lower systolic, diastolic and mean arterial BP than both placebo group and the baseline values in addition to increased serum antioxidant capacity</td>
</tr>
<tr>
<td>Sahakyan et al.74</td>
<td>Prospective cohort</td>
<td>384</td>
<td>34.8 ± 10.4</td>
<td>To look for the association of markers of inflammation and endothelial dysfunction with the development of hypertension</td>
<td>15 years</td>
<td>sVCAM-1 as a marker of endothelial dysfunction was the strongest predictor of hypertension risk in individuals with type 1 diabetes. This association was independent of the presence of diabetic nephropathy</td>
</tr>
<tr>
<td>Wang et al.75</td>
<td>Case-control study</td>
<td>1600</td>
<td>60.8</td>
<td>To test the association between the serum levels of markers of inflammation (CRP, IL-6, IL-1β, TNF receptor) and endothelial activation (SIAM-1) and risk of hypertension</td>
<td>5.9</td>
<td>After correction for the body mass index and waist circumference, there is no significant association between these markers and risk of hypertension</td>
</tr>
<tr>
<td>Chuang et al.76</td>
<td>Prospective cohort</td>
<td>2113</td>
<td>44.6 ± 13.4</td>
<td>To look for how the baseline CRP levels predict future incident hypertension</td>
<td>3.27</td>
<td>CRP levels were significantly associated with higher systolic BP, independent of baseline systolic or diastolic BP and obesity IL-17 serum levels are significantly higher in the prehypertensive group compared with the group with optimal BP Elevated plasma inflammatory markers and D-dimer were nonsignificantly associated with a higher risk of hypertension among initially healthy men</td>
</tr>
<tr>
<td>Yao et al.77</td>
<td>Cross-sectional</td>
<td>394</td>
<td>53.71 ± 6.30</td>
<td>To investigate whether IL-17, an autoimmune marker, has a role in hypertension development</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Sesso et al.78</td>
<td>Case-control study</td>
<td>792</td>
<td>47.5 ± 6.1</td>
<td>To examine the associations between incident hypertension and inflammatory markers such as CRP, IL-6, sICAM and D-dimer</td>
<td>14</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BP, blood pressure; CRP, C-reactive protein; LDL, low-density cholesterol; IL-17, interleukin-17; IL-6, interleukin-6; IL-1β, interleukin-1β; NA, not applicable; TNF, tumor necrosis factor; SIAM-1, soluble intercellular adhesion molecule-1; sICAM, soluble intracellular adhesion molecule; VMCAM-1, vascular cell adhesion molecule-1.
oxidative stress and the development of hypertension. Recent studies focused primarily on the role of T cells in the development of hypertension. Recombinase-activating gene knockout mice lacking T and B cells demonstrated a blunted blood pressure increase in response to angiotensin II infusion and deoxycorticosterone acetatesalt hypertension. Interestingly, the adoptive transfer of T cells, but not B cells, restored the blood pressure response in these mice. The authors also demonstrated that activated T cells can stimulate the vascular production of superoxide. Mahdur et al. compared the effects of angiotensin II infusion in IL-17 knockout mice and control mice. Although the initial hypertensive response was similar, hypertension was not sustained in mice lacking IL-17. The authors concluded that IL-17-producing T cells are required for the development of sustained hypertension. In contrast to the proinflammatory actions of TH1 and T helper type 17 (TH17) lymphocytes, regulatory T cells suppress inflammatory reactions. IL-10 is one of the main cytokines produced by these cells. Exogenous IL-10 normalizes blood pressure and endothelial function in a rodent model of pregnancy-induced hypertension. Several experimental studies demonstrated the importance of regulatory T cells in the prevention of immune cell infiltration and the consequent development of hypertension.

Despite compelling evidence for T-cell involvement as part of the adaptive immune system in the generation and propagation of hypertension, it remains to be determined why T cells infiltrate the kidney, vascular wall and central nervous system. Is it simply a phenomenon secondary to chemokines produced from the reaction of the innate immune system, or is there a specific antigen, not yet identified, involved in the localized adaptive immune response?

The so-called ‘neoantigen’ term has been used to explain the putative roles of unknown (for now) antigens stimulating the innate immune system and presenting to the adaptive immune system. Neoantigens are endogenous molecules modified in response to oxidative stress, protein cleavage and intracellular release. Heat-shock proteins (HSPs) are candidate neoantigens in hypertension. These proteins are expressed in the cytoplasm and function as chaperones to guide protein folding. HSPs can stimulate innate and adaptive immune reactivity under stress conditions, such as increased ROS, sympathetic overactivity and increased angiotensin II. To confirm the putative role of HSPs as the drivers of low-grade inflammation in hypertension, Parra et al. studied three different types of rat hypertension models. Each model had a 2–4-fold increase in renal HSP70 expression. Furthermore, T cells isolated from the spleens demonstrated a significant 2–9-fold increased proliferative response when cultured in medium containing HSP70 compared with controls. The same group confirmed the role of HSP70 as part of a likely autoimmune process in an elaborately designed rat study.

A diet rich in salt is implicated as a possible cause of increased inflammation and the autoimmune response. This may be partially due to the induction of pathogenic TH17 cells. IL-17-producing CD4 (+) helper T cells are a newly described sub-population of T cells, and these cells have a pivotal role in autoimmune diseases. Experimental studies demonstrated that environmental factors boost the growth of TH17 lymphocytes. Increased salt in the diet may lead to the growth of TH17 cells and upregulation of proinflammatory cytokines, such as GM-CSF (granulocyte–macrophage colony-stimulating factor), TNF-α and IL-2. Increased salt intake can also affect the innate immune system. This salt-induced increased inflammatory milieu may be another explanation for triggering autoimmunity in hypertension.

**HUMAN DATA SUPPORTING THE ROLE OF AUTOIMMUNITY IN HYPERTENSION**

There is no large-scale clinical evidence demonstrating the role of T cells in the pathogenesis of human hypertension. The possibility of a pathogenic role for lymphocytes in essential hypertension is based on observations in patients with AIDS. Seaberg et al. evaluated 5578 participants from the Multicenter AIDS Cohort Study. The authors demonstrated that HIV-positive male patients not taking antiretroviral therapy were significantly less likely than HIV-negative men to have systolic hypertension, as were men taking mono/combotherapy. This difference was attributed to a low level of circulating CD4+ T cells. Patients undergoing highly active antiretroviral therapy with normal levels of CD4+ T cells had comparable rates of hypertension as individuals without AIDS. Other small studies also lend support to the role of lymphocytes and HSP70 in human hypertension.

**GUT MICROBIOTA AND HYPERTENSION: A NEW PARADIGM**

The gut microbiota is dominated to a large extent by Firmicutes and Bacteroidetes and to a lesser extent by Actinobacteria and Proteobacteria. Gut microbiota may have a role in the development of cardiovascular disease, including arteriosclerosis and hypertension.

The Firmicutes to Bacteroidetes ratio was recently reported as increased in SHRs, angiotensin II-induced hypertensive rats and a small group of humans with essential hypertension. In addition, the oral administration of minocycline reduced both the Firmicutes to

**Figure 2** Association between gut flora, systemic inflammation and the development of hypertension.
Bacteroidetes ratio and the blood pressure of SHRs and rats with angiotensin II-induced hypertension. Evidence linking gut microbiota to hypertension include the observation that the consumption of milk fermented with Lactobacilli lowered blood pressure in hypertensive humans and that phenylacetyl glutamine, a gut microbial metabolite, has an antihypertensive effect. A recent meta-analysis in humans showed that probiotic consumption modestly decreased both systolic BP and diastolic BP, with a greater effect when at least 10^9 colony-forming units are consumed for at least 8 weeks and if multiple species of probiotics are consumed.

One mechanism relating gut microbiota to hypertension is an increased level of toxic metabolites, including p-cresol sulfate, indoxyl sulfate and trimethylamine N-oxide, which are known by-products of protein fermentation by the gut microbiota. In addition, the production of short-chain fatty acids by the gut microbiota can affect blood pressure by interaction with renal sensory nerves and an increase in renin secretion.

Perhaps, more importantly, gut microbiota, particularly with regard to intestinal wall inflammation, has been linked to the presence and severity of systemic inflammation. Several studies have shown that the level of Gram-negative bacteria endotoxin and bacterial DNA fragments in the systemic circulation are correlated with increased plasma CRP, IL-6 and -lactate. Interestingly, -lactate is a marker of intestinal wall permeability to bacteria and toxins from the gut lumen.

Therefore, this preliminary evidence shows that gut microbiota may be related to hypertension (Figure 2). Studies are needed to highlight the underlying mechanisms in different hypertensive species, such as Dahl salt-sensitive and salt-resistant rats and SHRs, for projection in human studies.

CONCLUSION

Accruing experimental and clinical evidence supports the inflammatory and autoimmune aspects of essential hypertension. Oxidative stress and inflammatory injury, both in the renal interstitium and vascular wall, may lead to mechanistic changes, which culminate in elevated blood pressure. However, because oxidative stress and inflammation are inseparably interconnected and can trigger and amplify each other, it is difficult to determine which precedes the other. Although it is clear that innate and adaptive immune systems are involved in the development of essential hypertension, it is premature at this time to define hypertension as an autoimmune disease. Although much progress has been made, further studies are needed to identify specific antigen(s) or factor(s) that drive low-grade inflammation and stimulate the adaptive immune response in subjects with essential hypertension.

CONFLICT OF INTEREST

The authors declare no conflict of interest.


